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Abstract
In the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial,
a pharmaco-invasive (PI) strategy was compared with primary percutaneous
coronary intervention (pPCI) in ST-segment-elevation myocardial infarction
patients presenting within 3 hours after symptom onset but unable to undergo
pPCI within 1 hour. At 30 days, the PI approach was associated with a nominally
but nonstatistically significant lower incidence of the composite primary end point
of death, shock, congestive heart failure, and reinfarction when compared with
pPCI. The aim of the present study was to determine the effect of these strategies
on 1-year mortality.
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Guidelines recommend a primary percutaneous coronary intervention (pPCI) as the preferred reperfusion modality 
in patients presenting with ST—segment-elevation myocar-
dial infarction (STEMI).1,2 Because most STEMI patients ini-
tially present to hospitals without PCI facilities, performing a 
pPCI in a timely fashion constitutes a significant logistic chal-
lenge in many healthcare systems across the world. Despite 
Background—In the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial, a pharmaco-invasive (PI) 
strategy was compared with primary percutaneous coronary intervention (pPCI) in ST—segment-elevation myocardial 
infarction patients presenting within 3 hours after symptom onset but unable to undergo pPCI within 1 hour. At 30 days, 
the PI approach was associated with a nominally but nonstatistically significant lower incidence of the composite primary 
end point of death, shock, congestive heart failure, and reinfarction when compared with pPCI. The aim of the present 
study was to determine the effect of these strategies on 1-year mortality.
Methods and Results—Vital status at 1 year was available in 936 of 944 (99.2%) and 941 of 948 (99.3%) patients in the 
PI and pPCI arm, respectively. At 1 year, all-cause mortality rates (6.7% versus 5.9%) were similar for PI and pPCI-
treated patients (P=0.49; risk ratio, 1.13; 95% confidence interval, 0.79–1.62). Cardiac mortality rates were similar as 
well (4.0% versus 4.1%, P=0.93; risk ratio, 0.98; 95% confidence interval, 0.62–1.54). Overall, only 34 patients died 
between day 30 and 1 year, 20 in the PI arm and 14 in the pPCI arm, of whom 20 died of noncardiac reasons (13 in the 
PI and 7 in the pPCI arm). There was no significant difference in 1-year all-cause mortality between the 2 groups among 
the prespecified key subgroups.
Conclusions—At 1 year, mortality rates in the PI and pPCI arms were similar in ST—segment-elevation myocardial 
infarction patients presenting within 3 hours after symptom onset and unable to undergo pPCI within 1 hour.
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concerted efforts to decrease transfer times, PCI-related sys-
tem delays remain substantial in many countries.3,4 Because 
these delays clearly have an unfavorable effect on morbidity 
and mortality,4,5 early fibrinolysis followed by timely angiog-
raphy often constitutes a faster reperfusion option in many 
patients than transfer for standard primary PCI.
In the Strategic Reperfusion Early After Myocardial Infarction 
(STREAM) study, we explored the strategy of prehospital fibri-
nolysis with bolus tenecteplase given before transport to a PCI-
capable hospital, followed by timely coronary angiography, in 
STEMI patients presenting within 3 hours but unable to undergo 
primary PCI within 1 hour.6,7 The primary end point was the com-
posite of death, shock, congestive heart failure, and reinfarction. 
At 30 days, we found that the pharmaco-invasive (PI) approach 
was associated with a nominally (not statistically significant) 
lower primary end point compared with primary PCI. Because 
of an excess of bleeding complications in the elderly, includ-
ing intracranial hemorrhage (ICH), the dose of tenecteplase 
was reduced by 50% in patients aged >75 years, after enroll-
ing ≈20% of the ultimate study population. After implementing 
the age-adjusted dose, no more ICH were seen in patients aged 
≥75 years assigned to the PI arm, but a small nonsignificantly 
increased risk of ICH remained in the total population studied.
We also observed a nonsignificant 1.5% absolute lower inci-
dence of both cardiogenic shock and congestive heart failure in 
the PI arm. In the Comparison of Angioplasty and Prehospital 
Thrombolysis in Acute Myocardial Infarction (CAPTIM) study, 
prehospital fibrinolysis in the subset of STEMI patients present-
ing within 2 hours of symptom onset was associated with lower 
30-day rates of both cardiogenic shock and death, as compared 
with transfer for primary PCI.8 A combined analysis of the 
CAPTIM and Which Early ST-Elevation Myocardial Infarction 
Therapy (WEST) studies also suggests a beneficial effect at 1 
year from a PI therapy in patients presenting early after symptom 
onset.9 Furthermore, the 5-year data from the French Registry 
on Acute ST-Elevation Myocardial Infarction (FAST-MI) sug-
gested that fibrinolysis administered early in the prehospital 
settings resulted in lower mortality than pPCI during long-term 
follow-up.10 The aim of the present study was to evaluate 1-year 
mortality between the 2 treatment strategies in STREAM.
Methods
The design and primary results of The Strategic Reperfusion Early 
After Myocardial Infarction (STREAM, NCT00623623) study, an 
open-label, prospective, randomized, parallel, comparative, and inter-
national multicenter trial, have been reported previously.6,7 The study 
protocol was approved by national regulatory authorities as well as 
the local ethics committee at each study center. Patient’s informed 
consent was obtained. In summary, patients were eligible for enroll-
ment in STREAM if they presented within 3 hours of symptom onset, 
demonstrated acute STEMI on their qualifying ECG (at least 2 mm in 
2 contiguous peripheral or precordial leads), and could not undergo 
pPCI within 1 hour after first medical contact. The emphasis of the 
trial was on prehospital randomization, but in an amendment, recruit-
ment was extended to patients presenting to community hospitals 
without PCI facilities but with access to PCI facilities in an estab-
lished hub-and-spoke relationship. Ultimately, 4 out of 5 patients 
were randomized in the prehospital setting.
The patients initially treated pharmacologically received 
tenecteplase coupled with antiplatelet and anticoagulant therapy fol-
lowed by coronary angiography within 6 to 24 hours. In the event 
that there was <50% ST-resolution in the single lead with maximum 
elevation, or clinical evidence of failed reperfusion 90 minutes 
after fibrinolysis, rescue coronary intervention was performed. 
Tenecteplase was administered in a weight-based dose and combined 
with enoxaparin, aspirin, and clopidogrel according to current guide-
lines. Urgent coronary angiography in the PI arm was permitted at 
any time should hemodynamic or electric instability, worsening isch-
emia, or progressive or sustained ST-elevation develop, which in the 
judgment of the investigator required immediate coronary interven-
tion. This PI strategy was compared with pPCI performed accord-
ing to guideline based, best accepted local practice with early use 
of concomitant antiplatelet and anticoagulant medications as well as 
additional discretionary glycoprotein IIb/IIIa antagonists. All patients 
were transferred to a PCI-capable hospital; for those non-PCI com-
munity hospitals participating, a well-developed hub-and-spoke rela-
tionship with a PCI-capable site was required. The primary end point 
of the trial was the 30-day composite comprising all-cause death, 
shock, heart failure, and reinfarction. Single efficacy end points as 
well as safety end points consisting of ischemic stroke, ICH, nonin-
tracranial bleeding, and other serious clinical events were recorded 
and are defined in the Appendix of the 30-day results article.7 Cardiac 
mortality includes the following causes of death: reinfarction, car-
diogenic shock, arrhythmia/sudden death, asystole/cardiac arrest, 
cardiac rupture, or ‘other cardiac’ event, but excluded stroke or ICH, 
major (non-ICH) bleeding, or ‘other noncardiac’ event.
After 21% of the ultimate population had been enrolled the Executive 
Committee, with the advice of the Data and Safety Monitoring Board, 
amended the protocol on August 24, 2009 to reduce the dose of 
tenecteplase by 50% in patients aged ≥75 years because of an excess 
of ICH in this age category. The dose adjustment was based on previ-
ous work by Larson et al.9 Additionally, to better align the ECG entry 
criteria with contemporary STEMI trials the inclusion criteria for 
inferior myocardial infarction were changed at that time from ≥3 mm 
ST-elevation in 2 contiguous inferior leads to ≥ 2mm ST-elevation in 2 
contiguous inferior leads.
The STREAM trial was designed as a proof-of-concept study. All 
statistical tests were of an exploratory nature. Baseline characteristics 
are reported as mean (SD) or number (%) where appropriate. One-
year mortality event rates were estimated by using the Kaplan–Meier 
method, and a risk ratio (RR) with a 95% confidence interval (CI) was 
calculated. In addition, the event times were compared between treat-
ment groups using a log-rank test. For cardiac mortality, we present 
the complement of the cumulative incidence function with noncardiac 
death as competing risk. A risk ratio at 1 year with a 95% CI was 
calculated. Gray’s test was used to compare the cumulative incidence 
functions, that is the subdistribution hazards, between the 2 treatment 
groups over the whole follow-up time. In addition, the cause-specific 
hazards for cardiac death were calculated by censoring the noncardiac 
deaths. Note that the cumulative incidence functions are influenced by 
the number of patients who experienced the competing risk, whereas 
the cause-specific hazards are not. We also undertook the following 
prespecified subgroup analyses: age, sex, Killip class, time to ran-
domization, place of randomization, infarct location, systolic blood 
pressure, weight, history of diabetes mellitus or hypertension, throm-
bolysis in myocardial infarction, risk score, and before or after the 
protocol amendment. We evaluated the interactions between treatment 
and subgroups. All analyses were by intention to treat and done with 
SAS (version 9.2). P values are provided for descriptive purposes only.
Results
Vital status at 1 year was available for 936 of 944 (99.2%) and 
941 of 948 (99.3%) patients in the PI and pPCI arm, respec-
tively. Key baseline characteristics, shown in Table 1, were 
similar in both treatment arms.
At 1 year, 63 patients (6.7%) had died in the PI arm, ver-
sus 56 (5.9%) in the pPCI arm (P=0.49; RR, 1.13; 95% CI, 
0.79–1.62). Cardiac mortality at 1 year was also similar for 
both treatment strategies: 4.0% and 4.1% for PI treatment and 
pPCI, respectively (P=0.93; RR, 0.98; 95% CI, 0.62–1.54). 
There was a numeric excess of 8 noncardiac deaths in the PI 
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arm (25 versus 17 with pPCI). Nine patients died from a stroke 
or intracranial hemorrhage in the PI arm, versus 4 in the pPCI 
arm; 1 patient had a fatal (non-ICH) bleeding complication in 
the pPCI arm, versus none in the PI arm. As shown by the sur-
vival curves in Figure 1, all-cause mortality rates tended to be 
numerically but not statistically significantly higher beyond 
the first month for the PI arm versus pPCI (log-rank P=0.495). 
For cardiac mortality, however, survival curves were superim-
posable (Gray’s test P=0.923, Figure 2). Also, the cause-spe-
cific hazard analysis showed no significant difference between 
the treatment groups (RR, 0.98; 95% CI, 0.62–1.55; P=0.94)
Among the patients who were alive at 30 days, all-cause mor-
tality rates to 1 year were low in both treatment arms. Overall, 34 
patients died between day 30 and 1 year, 20 in the PI arm (2.2%) 
and 14 in the pPCI arm (1.6%). There were 7 cardiac deaths 
in each treatment arm, but there was an excess of 6 noncardiac 
deaths in the PI arm. In this group, 2 patients died from a stroke 
and 11 from other noncardiac causes after day 30; in the pPCI 
arm, 1 patient died from a major bleeding, whereas 6 died from 
other noncardiac causes. Among the 7 patients in the PI arm who 
experienced a stroke or intracranial hemorrhage but survived 
through the first month, only 1 died between day 30 and 1 year. 
Table 2 gives an overview of the causes of death up to 1 year.
Up to 30 days, significantly more patients underwent coro-
nary bypass surgery in the PI arm (44 versus 20 after pPCI). 
Of these, only 1 patient in each group died before 30 days. 
No coronary bypass surgery–managed patients died beyond 
30 days in the pPCI group, versus 4 in the PI arm, of whom 2 
initially underwent rescue PCI and died from a cardiac cause.
There was no significant difference in 1-year all-cause 
mortality rates between patients randomized to PI therapy or 
pPCI among the prespecified key subgroups except for ran-
domization before the amendment (Figure 3). We observed 
a significant treatment interaction between patients random-
ized before versus after the amendment (P=0.035), however. 
The survival curves for all-cause mortality before versus after 
the amendment are shown in Figure 4. Before the amend-
ment (at which time 21% of the total patient population had 
been enrolled) there was a significant excess of death in the 
PI group versus pPCI (9.9% versus 4.3% for pPCI, P=0.031; 
RR, 2.32; 95%CI, 1.09–7.51). In contrast, the curves for both 
treatment arms converged after implementing the amendment 
(5.9% versus 6.3%, respectively, P=0.71; RR, 0.93; 95% CI, 
0.61–1.39). Cardiac mortality rates were not significantly 
different between the PI and pPCI arms before (4.7% versus 
3.2%, respectively; P=0.455) or after the amendment (3.9% 
versus 4.4%, respectively; P=0.634, Pinteraction=0.380).
Before implementing the amendment, there were 9 cardiac 
deaths in the PI arm and 6 in the pPCI arm at 1 year. Of the 10 
noncardiac deaths in the PI arm, 5 died from an ICH or stroke. 
Before the amendment, only 2 patients in the pPCI arm died 
from a noncardiac cause (including 1 from a major bleeding).
Discussion
Although pPCI is the reperfusion strategy of choice in STEMI 
patients when performed by an experienced team in a timely 
Table 1. Key Baseline Characteristics
Pharmaco-Invasive 
(n=944)
Primary PCI  
(n=948)
Age, y (mean±SD) 59.7±12.4 59.6±12.5
Age ≥75 y, n (%) 134/944 (14.2%) 121/948 (12.8%)
Female, n (%) 194/944 (20.6%) 208/948 (21.9%)
Previous MI, n (%) 81/940 (8.6%) 98/947 (10.3%)
Diabetes mellitus, n (%) 113/934 (12.1%) 123/939 (13.1%)
Weight <60 kg, n (%) 47/944 (5.0%) 54/948 (5.7%)
Killip class II–IV, n (%) 53/895 (5.9%) 50/894 (5.6%)
TIMI risk score ≥5, n (%) 116/868 (13.4%) 119/867 (13.7%)
Time to randomization from symptom onset
  0 to <1 h, n (%) 170/944 (18.0%) 187/948 (19.7%)
  ≥1 to <2 h, n (%) 475/944 (50.3%) 456/948 (48.1%)
  ≥2 h, n (%) 299/944 (31.7%) 305/948 (32.2%)
Infarct location
  Anterior (n, %) 453/942 (48.1%) 431/946 (45.6%)
  Inferior (n, %) 468/942 (49.7%) 497/946 (52.5%)
  Other (n, %) 21/942 (2.2%) 18/946 (1.9%)
Place of randomization
  Ambulance, n (%) 768/944 (81.4%) 761/948 (80.3%)
  Community hospital, n (%) 176/944 (18.6%) 187/948 (19.7%)
MI indicates myocardial infarction; PCI, percutaneous coronary intervention; 
and TIMI, thrombolysis in myocardial infarction.
Figure 1. All-cause mortality Kaplan–Meier curves. 
PCI indicates percutaneous coronary intervention; 
and TNK, Tenecteplase. 
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manner, fibrinolysis remains a more feasible and often the 
only available reperfusion modality in many regions across the 
world. STREAM assessed the merits of predominantly prehos-
pital fibrinolysis with contemporary antithrombotic cotherapies 
followed by a planned angiography or rescue PCI if appropri-
ate in STEMI patients presenting early but unable to undergo 
primary PCI within 60 minutes, as compared with transport for 
primary PCI. The 1-year results from STREAM confirm that 
mortality rates were low, and that a PI strategy resulted in a 
similar mortality as pPCI. Among the 1792 patients surviving 
beyond 30 days, there were only 34 more deaths within the 
first year of follow-up, representing less than one third of total 
1-year mortality. Although we did observe an excess of 6 non-
cardiac deaths after 30 days in the PI arm, the cardiac as well 
as all-cause mortality were similar between the 2 arms. These 
findings were consistent across key prespecified subgroups.
The mortality benefit of transfer for pPCI over on-site fibri-
nolysis significantly declines when transfer times, including 
door-in-door-out delays, increase.4 Despite the per-protocol 
mandate of an expected delay of at least 60 minutes for pPCI, 
treatment delays were remarkably short in STREAM, in part 
because of the prehospital triage. In fact, the median delay 
between first medical contact and primary PCI was 107 min-
utes, well within the 120-minute guideline-recommended 
target and shorter than often reported in other trials and real-
world registries.1,2 The relatively short treatment delays in 
both treatment arms might in part explain the lack of a dif-
ference in 1-year mortality between the 2 reperfusion strat-
egies in STREAM. Outside the setting of a clinical trial, or 
in the absence of prehospital triage, however, transfer delays 
to achieve pPCI are expected to be considerably longer.4,11 
Although unproven, one could speculate that, in real-world 
circumstances, a PI strategy could lead to a greater clinical 
benefit compared with transfer for primary PCI, given the 
typically longer PCI-related delays.8
In STREAM, significantly more lytic-treated patients 
underwent coronary bypass surgery within the first 30 days.7 
This is likely attributable in part to the planned angiography 
between 6 and 24 h after successful fibrinolysis, allowing for 
a more considered appraisal of the best and more complete 
revascularization in patients with multi-vessel disease as 
compared with pPCI patients. Because the number of deaths 
was also low among patients managed with bypass surgery, 
it remains unclear from our data whether the longer interval 
before angiography followed by the appropriate mode of 
revascularization including coronary bypass surgery would 
result in improved outcome. It is likely that any potential ben-
efit of such an approach would only become apparent after a 
longer follow-up.
Pooled data from the CAPTIM and WEST trials suggest 
that the risk of death at 1 year is lower with early fibrinolysis 
compared with pPCI in patients presenting within 2 hours of 
symptom onset.9 In the CAPTIM trial, prehospital fibrinolysis 
was associated with a lower risk of both cardiogenic shock and 
death in patients presenting early after symptom onset, com-
pared with transport for primary PCI.8 In STREAM, the com-
posite end point of death, shock, congestive heart failure, and 
reinfarction was numerically lower in the PI arm at 30 days. 
This difference was mainly driven by a nonsignificant higher 
absolute 1.5% incidence of cardiogenic shock and congestive 
heart failure after pPCI. At 1 year, this beneficial trend did 
Table 2. Causes of Death at 1 Year
Cause
Pharmaco-Invasive  
(n=944)
Primary PCI  
(n=948)
Up to 1 y
After  
Day 30 Up to 1 y
After  
day 30
Cardiac 38/63 7/20 39/56 7/14
  Reinfarction 0/63 0/20 3/56 1/14
  Cardiogenic shock 19/63 3/20 21/56 2/14
  Cardiac arrest/sudden death* 13/63 3/20 11/56 4/14
  Other cardiac 6/63 1/20 3/56 0/14
Noncardiac† 25/63 13/20 17/56 7/14
  Stroke or ICH 9/63 2/20 4/56 0/14
  Major (non-ICH) bleeding 0/63 0/20 1/56 1/14
  Other noncardiac event 16/63 11/20 12/56 6/14
Causes of death were reported by the investigators. ICH indicates intracranial 
hemorrhage; and PCI, percutaneous coronary intervention.
*Cardiac arrest/sudden death includes death reported to be caused by 
arrhythmia, asystole, or cardiac rupture; there were 6 cardiac ruptures in the 
pharmaco-invasive arm, vs 1 after primary PCI.
†Noncardiac causes of death prospectively collected as 3 categories: stroke 
or ICH, major (non-ICH) bleeding, or other noncardiac event.
Figure 2. Complement of cardiac mortality 
cumulative incidence curves. PCI indicates 
percutaneous coronary intervention; and TNK, 
Tenecteplase.
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not translate into lower mortality rates, however, perhaps in 
part related to the offsetting small excess of noncardiac death. 
In addition, the effect of a reduction in cardiogenic shock or 
heart failure might need longer follow-up to detect an effect 
on mortality as suggested by observations of other STEMI 
treatment strategies. Indeed, lower rates of cardiogenic shock 
in the early-presenting patients with fibrinolysis in CAPTIM 
were associated with significantly lower 5-year mortality 
rates.12 In addition, observational 5-year data from the French 
FAST-MI study suggest a significant long-term survival ben-
efit for prehospital lysis versus primary PCI as well.13
After approximately one fifth of the planned popula-
tion had been enrolled, the tenecteplase dose was halved in 
patients aged ≥75 years because of an excess of intracranial 
hemorrhage in this age group. This change was recommended 
by the Data and Safety Monitoring Board, and inspired by 
a successful strategy of half-dose tenecteplase followed by 
immediate transfer applied in STEMI patients presenting 
to rural hospitals.14 In the same amendment, the inclusion 
threshold of 3 mm elevation in at least 2 contiguous leads 
was decreased to 2 mm for inferior wall myocardial infarc-
tion as well. We observed a significant treatment interaction 
Figure 3. Selected subgroups. Event rates are estimated Kaplan–Meier estimates. Interactions are assessed using a χ2 test. °Calculated 
using Taylor’s method, all other confidence intervals are calculated using Fieller’s method. $Assessment of interaction only included 
anterior or inferior infarct because of a lack of events in the other group. MI indicates myocardial infarction; NC, not calculated; PInv, 
pharmaco-invasive strategy; and pPCI, = primary percutaneous coronary intervention.
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for 1-year all-cause mortality in patients randomized before 
versus after the amendment. In essence, the mortality curves 
for both arms converged after the amendment. Because no 
intracranial hemorrhages were observed in the elderly after 
reducing the tenecteplase bolus, the reduction of tenecteplase 
bolus might indeed have played a role in mitigating the 
excess mortality after the amendment. Our observations also 
suggest that a half-dose bolus might be a safer dosage for 
elderly patients.14 Because mortality rates were low, however, 
we cannot exclude the play of chance. In addition, other fac-
tors not related to the amendment might have contributed to 
the convergence of mortality rates. After the initial start-up 
of the trial, more international and perhaps less experienced 
sites started to randomize patients, possibly contributing to 
the increase in deaths in the primary PCI arm. On the other 
hand, more experience with the rigorous in- and exclusion 
criteria with time might have contributed to the decrease in 
mortality in the PI arm as well.
STREAM was an exploratory randomized, clinical trial 
without a primary hypothesis. The current findings do not 
apply to patients who would be able to undergo pPCI within 
1 hour after first medical contact, or patients who present 
beyond 3 hours after symptom onset, or treated with other 
fibrinolytic agents. Taken together, our 1-year findings sup-
port the current 120-minute guideline-recommended maxi-
mum tolerable delay overall for transfer to primary PCI as 
well as the shorter time window of 60 minutes for high-
risk patients presenting early.1,2 Our results indicate that if 
these time windows cannot be met, a PI strategy as used in 
STREAM is likely to be as good as pPCI. We also observed 
an increased risk of ICH early in the trial, but this risk was 
significantly attenuated after implementing the amendment. 
This would imply that patients aged ≥75 years might need 
to be treated with only half-dose tenecteplase, although 
a formal recommendation awaits further analyses from 
this trial as well as future studies to come. In conclusion, 
because timely pPCI remains unattainable in many health-
care systems across the world, a dose-adjusted PI approach 
as studied in STREAM offers a safe and effective alternative 
reperfusion therapy strategy to a substantial proportion of 
STEMI patients worldwide.
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CLINICAL PERSPECTIvE
In spite of significant reductions in door-to-balloon time, early mortality rates after primary percutaneous coronary interven-
tion (PCI) remained unchanged, indicating that other components of the total ischemic time such as transport times need to be 
targeted. Fast transport of a ST—segment-elevation myocardial infarction patient to a PCI hospital is not always possible. In 
these patients early fibrinolysis, followed by timely angiography, constitutes an alternative reperfusion strategy. In the Strategic 
Reperfusion Early After Myocardial Infarction (STREAM) study, we compared a pharmaco-invasive treatment with transfer 
for primary PCI in patients presenting within 3 hours after symptom onset but unable to undergo primary PCI within 1 hour. 
The pharmaco-invasive strategy consisted of prehospital tenecteplase given before transport, followed by coronary angiography 
between 6 and 24 hours, or by rescue coronary intervention if there was evidence of failed reperfusion. At 1 year, STREAM 
showed that the pharmaco-invasive strategy resulted in similar mortality rates as transfer for routine primary PCI. These findings 
support the current 60-minute guideline-recommended maximal tolerable delay for transfer for primary PCI in high-risk patients 
presenting early. In addition, the increased risk of intracranial hemorrhage with fibrinolysis observed early in the trial was sig-
nificantly attenuated after halving the bolus tenecteplase in patients aged ≥75 years. Taken together, because timely primary PCI 
remains unattainable in many healthcare systems, an age-adjusted pharmaco-invasive approach as studied in STREAM seems to 
offer a safe and effective alternative reperfusion therapy to a substantial proportion of ST-segment elevation myocardial infarction 
patients worldwide. More studies with half-dose tenecteplase in elderly are needed to confirm these findings.
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SUPPLEMENTAL APPENDIX 
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Chapon, B Cheval, J Claudel, P Cohen Tenoudji, P Coste, V Debierre, R Domergue, K 
Echahed, C El Khoury, E Ferrari, P Garrot, P Henry, B Jardel, R Jilwan, V Julie, R 
Ketelers, F Lapostolle, J Le Tarnec, B Livarek, Y Mann, X Marchand, F Pajot, T Perret, P 
Petit, V Probst, A Ricard Hibon, C Robin, A Salama, E Salengro, D Savary, F Schiele, L 
Soulat, X Tabone, P Taboulet, M Thicoïpe, J Torres, C Tron, G Vanzetto, L Villain-Coquet 
Germany (58 patients): S Piper, HC Mochmann, L Nibbe, U Schniedermeier, H Heuer, F 
Marx, W Schöls, W Lepper, R Grahl, G Muth. Greece (76 patients): G Lappas, I Mantas, E 
Skoumbourdis, C Dilanas, I Kaprinis, I Vogiatzis, I Zarifis, G Spyromitros, S 
Konstantinides, D Symeonides. Italy (25 patients): GP Rossi, F Bermano, S Ferlito, P 
Paolini, L Valagussa, F Della Rovere, F Miccoli, M Chiti, W Vergoni, M Comeglio, G 
Percoco, M Valgimigli. Norway (55 patients): K Berget, O Skjetne, H Schartum-Hansen, K 
Andersen, OJ Rolstad Peru (3 patients): ON Aguirre Zurita, RP Castillo León, AC Villar 
Quiroz Poland (29 patients): A Glowka, P Kulus. Russian Federation (327 patients): S 
Kalinina, A Bushuev, O Barbarash, N Tarasov, I Fomin, E Makarov, V Markov, A 
Danilenko, E Volkova, A Frolenkov, N Burova, A Yakovlev, L Elchinskaya, S Boldueva, 
G Klein, I Kolosova, E Ovcharenko, R Fairushin. Serbia (134 patients): S Andjelic, V 
Vukcevic, A Neskovic, M Krotin, T Rajkovic, M Pavlovic, J Perunicic, S Kovacevic, V 
Petrovic, V Mitov. Spain (167 patients): A Ruiz, A García-Alcántara, M Martínez, J Díaz, 
MA Paz, FL Manzano, C Martín, C Macaya, E Corral, JJ Fernández, F Martín, R García. 
United Kingdom (60 patients): N Siriwardena, O Rawstorne, A Baumbach, G Manoharan, I 
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